BIO3 — Biotest AG Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMid CapMomentum Trap

Annual income statement for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	484	516	516	685	726
Cost of Revenue
Gross Profit	130	80.7	125	280	224
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	486	563	533	541	632
Operating Profit	-1.3	-47.1	-16.6	144	94.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-30	-62.6	-30.8	106	46.5
Provision for Income Taxes
Net Income After Taxes	-31.4	-63.3	-31.6	127	26.3
Net Income Before Extraordinary Items
Net Income	-31.4	-63.3	-31.6	127	26.3
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-32.2	-65	-32.5	127	26.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-0.83	-1.69	0.449	1.53	0.268
Dividends per Share